BRAF and melanoma: Well-known examples are the RAS-activating mutations in BRAF actionable melanoma or the T790M resistance mutation in non-small cell lung cancer (NSCLC) under therapy with first or second generations tyrosine kinase inhibitors (TKIs) directed against the EGFR receptor [11].